Nuvasive (Nasdaq:NUVA) this week posted fourth-quarter results that missed overall estimates on Wall Street.

The San Diego-based orthopedic company reported profits of $24.1 million, or 42¢ per share, on sales of $305.5 million, for the three months ended Dec. 31, 2022, on sales growth of 1.12% compared to Q4 2021. It also had a profit gain over the same period when it reported $36.7 million in losses.

Adjusted to exclude one-time items, earnings per share were 43¢, 8¢ behind The Street, where analysts were looking for sales of $311.01 million.

“Looking back at 2022, I am proud of our team for delivering another year of above-market, net sales growth,” CEO Chris Barry said in a news release. “Looking ahead, I couldn’t be more excited to join forces with Globus Medical to create a leading, global musculoskeletal technology company. Our complementary commercial organizations and product portfolios make a strong financial profile and value creation opportunity for shareholders—while furthering our ability to increase customer reach and change more patient lives.”

NuVasive announced on February 9 that it would merge with Globus medical to form a global musculoskeletal company. The deal valued NuVasive at $3.1 billion.

For fiscal 2023, the company anticipates net sales growth of 6-8%.

Shares in NUVA were down slightly to $43.84 apiece.